Drugs / JBM-TC4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02289365 | Nov 2014 → Dec 2016 | radiodermatitis | Joben Bio-Medical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JBM-TC4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02289365 ↗ |
| Route | Oral | “2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period...” NCT02289365 ↗ |